Skip to main content

Advertisement

SpringerLink
Log in

Pharmacological Management of Opioid Use Disorder in Pregnant Women

  • Therapy in Practice
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Opioid misuse during pregnancy is associated with negative outcomes for both mother and fetus due not only to the physiological effects of the drug but also to the associated social, medical and mental health problems that accompany illicit drug use. An interdisciplinary approach to the treatment of opioid use disorder during pregnancy is most effective. Ideally, obstetric and substance use treatment are co-located and ancillary support services are readily available. Medication-assisted treatment with methadone or buprenorphine is intrinsic to evidence-based care for the opioid-using pregnant woman. Women who are not stabilized on an opioid maintenance medication experience high rates of relapse and worse outcomes. Methadone has been the mainstay of maintenance treatment for nearly 50 years, but recent research has found that both methadone and buprenorphine maintenance treatments significantly improve maternal, fetal and neonatal outcomes. Although methadone remains the current standard of care, the field is beginning to move towards buprenorphine maintenance as a first-line treatment for pregnant women with opioid use disorder, because of its greater availability and evidence of better neonatal outcomes than methadone. However, there is some evidence that treatment dropout may be greater with buprenorphine relative to methadone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pan IJ, Yi HY. Prevalence of hospitalized live births affected by alcohol and drugs and parturient women diagnosed with substance abuse at liveborn delivery: United States, 1999–2008. Matern Child Health J. 2013;17(4):667–76. doi:10.1007/s10995-012-1046-3.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Tolia VN, Patrick SW, Bennett MM, Murthy K, Sousa J, Smith PB, et al. Increasing incidence of the neonatal abstinence syndrome in US neonatal ICUs. N Engl J Med. 2015;372(22):2118–26. doi:10.1056/NEJMsa1500439.

    Article  PubMed  Google Scholar 

  3. Azadi A, Dildy GA 3rd. Universal screening for substance abuse at the time of parturition. Am J Obstet Gynecol. 2008;198(5):e30–2. doi:10.1016/j.ajog.2007.10.780.

    Article  PubMed  Google Scholar 

  4. Dawson AL, Razzaghi H, Arth A, Canfield MA, Parker SE, Reefhuis J, et al. Maternal exposures in the National Birth Defects Prevention Study: time trends of selected exposures. Birth Defects Res A Clin Mol Teratol. 2015;. doi:10.1002/bdra.23377.

    Google Scholar 

  5. Maeda A, Bateman BT, Clancy CR, Creanga AA, Leffert LR. Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes. Anesthesiology. 2014;121(6):1158–65. doi:10.1097/aln.0000000000000472.

    Article  PubMed  Google Scholar 

  6. Whiteman VE, Salemi JL, Mogos MF, Cain MA, Aliyu MH, Salihu HM. Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States. J Pregnancy. 2014;2014:906723. doi:10.1155/2014/906723.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA. 2012;307(18):1934–40. doi:10.1001/jama.2012.3951.

    Article  CAS  PubMed  Google Scholar 

  8. Jones HE, Finnegan LP, Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs. 2012;72(6):747–57. doi:10.2165/11632820-000000000-00000.

    Article  CAS  PubMed  Google Scholar 

  9. Martin CE, Longinaker N, Terplan M. Recent trends in treatment admissions for prescription opioid abuse during pregnancy. J Subst Abuse Treat. 2015;48(1):37–42. doi:10.1016/j.jsat.2014.07.007.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Young JL, Martin PR. Treatment of opioid dependence in the setting of pregnancy. Psychiatr Clin N Am. 2012;35(2):441–60. doi:10.1016/j.psc.2012.03.008.

    Article  Google Scholar 

  11. Hayford SM, Epps RP, Dahl-Regis M. Behavior and development patterns in children born to heroin-addicted and methadone-addicted mothers. J Natl Med Assoc. 1988;80(11):1197–200.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. American College of Obstetricians and Gynecologists. ACOG Committee opinion no. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012;119(5):1070–6. doi:10.1097/AOG.0b013e318256496e.

    Article  Google Scholar 

  13. Finnegan LP. Treatment issues for opioid-dependent women during the perinatal period. J Psychoact Drugs. 1991;23(2):191–201. doi:10.1080/02791072.1991.10472236.

    Article  CAS  Google Scholar 

  14. Arunogiri S, Foo L, Frei M, Lubman DI. Managing opioid dependence in pregnancy—a general practice perspective. Aust Fam Physician. 2013;42(10):713–6.

    PubMed  Google Scholar 

  15. National Board of Health. Guidance no. 42 on medical treatment of drug abusers in substitution treatment for opioid dependence, July 1st 2008. Copenhagen: National Board of Health; 2008.

  16. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S. Groupe d’Etudes Grossesse et Addictions. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend. 2006;82(3):250–7. doi:10.1016/j.drugalcdep.2005.10.001.

    Article  CAS  PubMed  Google Scholar 

  17. Ordean A, Kahan M, Graves L, Abrahams R, Boyajian T. Integrated care for pregnant women on methadone maintenance treatment: Canadian primary care cohort study. Can Fam Physician. 2013;59(10):e462–9.

    PubMed  PubMed Central  Google Scholar 

  18. Jones HE, Heil SH, O’Grady KE, Martin PR, Kaltenbach K, Coyle MG, et al. Smoking in pregnant women screened for an opioid agonist medication study compared to related pregnant and non-pregnant patient samples. Am J Drug Alcohol Abuse. 2009;35(5):375–80. doi:10.1080/00952990903125235.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Alshaarawy O, Anthony JC. Month-wise estimates of tobacco smoking during pregnancy for the United States, 2002–2009. Matern Child Health J. 2015;19(5):1010–5. doi:10.1007/s10995-014-1599-4.

    Article  PubMed  Google Scholar 

  20. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320–31. doi:10.1056/NEJMoa1005359.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Osborn DA, Jeffery HE, Cole M. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev. 2005;3:CD002059. doi:10.1002/14651858.CD002059.pub2.

    PubMed  Google Scholar 

  22. Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis. 1975;2(1–2):141–58.

    CAS  PubMed  Google Scholar 

  23. Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr. 1991;118(6):933–7.

    Article  CAS  PubMed  Google Scholar 

  24. Herzlinger RA, Kandall SR, Vaughan HG Jr. Neonatal seizures associated with narcotic withdrawal. J Pediatr. 1977;91(4):638–41.

    Article  CAS  PubMed  Google Scholar 

  25. Kandall SR, Albin S, Gartner LM, Lee KS, Eidelman A, Lowinson J. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev. 1977;1(2):159–69.

    Article  CAS  PubMed  Google Scholar 

  26. World Health Organization. Guidelines for the identification and management of substance use and substance use disorders in pregnancy. Geneva: World Health Organization; 2014.

    Google Scholar 

  27. Lu R, Liu X, Long H, Ma L. Effects of prenatal cocaine and heroin exposure on neuronal dendrite morphogenesis and spatial recognition memory in mice. Neurosci Lett. 2012;522(2):128–33. doi:10.1016/j.neulet.2012.06.023.

    Article  CAS  PubMed  Google Scholar 

  28. Sundelin-Wahlsten V, Sarman I. Neurobehavioural development of preschool-age children born to addicted mothers given opiate maintenance treatment with buprenorphine during pregnancy. Acta Paediatr. 2013;102(5):544–9. doi:10.1111/apa.12210.

    Article  PubMed  Google Scholar 

  29. Burns L, Conroy E, Mattick RP. Infant mortality among women on a methadone program during pregnancy. Drug Alcohol Rev. 2010;29(5):551–6. doi:10.1111/j.1465-3362.2010.00176.x.

    Article  PubMed  Google Scholar 

  30. Jones HE, Martin PR, Heil SH, Stine SM, Kaltenbach K, Selby P, et al. Treatment of opioid dependent pregnant women: clinical and research issues. J Subst Abuse Treat. 2008;35(3):245–59.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Roberts SC, Nuru-Jeter A. Women’s perspectives on screening for alcohol and drug use in prenatal care. Women’s Health Issues. 2010;20(3):193–200. doi:10.1016/j.whi.2010.02.003.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Roberts SC, Pies C. Complex calculations: how drug use during pregnancy becomes a barrier to prenatal care. Matern Child Health J. 2011;15(3):333–41. doi:10.1007/s10995-010-0594-7.

    Article  PubMed  PubMed Central  Google Scholar 

  33. National Collaborating Centre for Women’s and Children’s Health. Pregnancy and complex social factors: a model for service provision for pregnant women with complex social factors. London: Royal College of Obstetricians and Gynaecologists; 2010.

    Google Scholar 

  34. Hall JL, van Teijlingen ER. A qualitative study of an integrated maternity, drugs and social care service for drug-using women. BMC Pregnancy Childbirth. 2006;6:19. doi:10.1186/1471-2393-6-19.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Jones HE, Deppen K, Hudak ML, Leffert L, McClelland C, Sahin L, et al. Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers. Am J Obstet Gynecol. 2014;210(4):302–10. doi:10.1016/j.ajog.2013.10.010.

    Article  PubMed  Google Scholar 

  36. NSW Ministry of Health. Clinical guidelines for the management of substance use during pregnancy, birth and the postnatal period. Sydney: NSW Ministry of Health; 2014.

    Google Scholar 

  37. Fédération Française d’Addictologie. Stratégies thérapeutiques pour les personnes dépendantes des opiacés: place des traitements de substitution. Lyon: Ministère de la Santé et de la Protection Sociale; 2004.

    Google Scholar 

  38. Goler NC, Armstrong MA, Taillac CJ, Osejo VM. Substance abuse treatment linked with prenatal visits improves perinatal outcomes: a new standard. J Perinatol. 2008;28(9):597–603. doi:10.1038/jp.2008.70.

    Article  CAS  PubMed  Google Scholar 

  39. Ordean A, Kahan M. Comprehensive treatment program for pregnant substance users in a family medicine clinic. Can Fam Physician. 2011;57(11):e430–5.

    PubMed  PubMed Central  Google Scholar 

  40. Chang G, Carroll KM, Behr HM, Kosten TR. Improving treatment outcome in pregnant opiate-dependent women. J Subst Abuse Treat. 1992;9(4):327–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Sheehan M, Sheehan MG. Management of the pregnant substance abusing woman. Clin Obstet Gynecol. 2013;56(1):97–106. doi:10.1097/GRF.0b013e3182795878.

    Article  PubMed  Google Scholar 

  42. Jansson LM, Svikis D, Lee J, Paluzzi P, Rutigliano P, Hackerman F. Pregnancy and addiction: a comprehensive care model. J Subst Abuse Treat. 1996;13(4):321–9.

    Article  CAS  PubMed  Google Scholar 

  43. Unger A, Metz V, Fischer G. Opioid dependent and pregnant: what are the best options for mothers and neonates? Obstet Gynecol Int. 2012;2012:195954. doi:10.1155/2012/195954.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Lander LR, Marshalek P, Yitayew M, Ford D, Sullivan CR, Gurka KK. Rural healthcare disparities: challenges and solutions for the pregnant opioid-dependent population. W V Med J. 2013;109(4):22–7.

    Google Scholar 

  45. Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012;107(Suppl 1):5–27.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Gopman S. Prenatal and postpartum care of women with substance use disorders. Obstet Gynecol Clin N Am. 2014;41(2):213–28. doi:10.1016/j.ogc.2014.02.004.

    Article  Google Scholar 

  47. Sokol RJ, Martier SS, Ager JW. The T-ACE questions: practical prenatal detection of risk-drinking. Am J Obstet Gynecol. 1989;160(4):863–8 (discussion 868–70).

    Article  CAS  PubMed  Google Scholar 

  48. Russell M. New assessment tools for risk drinking during pregnancy. Alcohol Health Res World. 1994;18(1):55–61.

    Google Scholar 

  49. Bush K, Kivlahan D, McDonnell M, Fihn S, Bradley K. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158:1789–95.

    Article  CAS  PubMed  Google Scholar 

  50. Burns E, Gray R, Smith LA. Brief screening questionnaires to identify problem drinking during pregnancy: a systematic review. Addiction. 2010;105(4):601–14. doi:10.1111/j.1360-0443.2009.02842.x.

    Article  PubMed  Google Scholar 

  51. Benningfield MM, Arria AM, Kaltenbach K, Heil SH, Stine SM, Coyle MG, et al. Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women. Am J Addict. 2010;19(5):416–21. doi:10.1111/j.1521-0391.2010.00064.x.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Mozurkewich EL, Rayburn WF. Buprenorphine and methadone for opioid addiction during pregnancy. Obstet Gynecol Clin N Am. 2014;41(2):241–53. doi:10.1016/j.ogc.2014.02.005.

    Article  Google Scholar 

  53. Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev. 2013;12:CD006318. doi:10.1002/14651858.CD006318.pub3.

    PubMed  Google Scholar 

  54. Intergovernmental Committee on Drugs. National pharmacotherapy policy for people dependent on opioids. Canberra: Australian Government Department of Health and Ageing; 2007.

    Google Scholar 

  55. Fernández-Miranda JJ, Pereiro-Gómez C. Guía para el tratamiento de la dependencia de opiáceos [guidelines for treatment of opioid dependence]. Valencia: Socidrogalcohol [Spanish Scientific Society for the Study of Alcohol, Alcoholism and other Drug Dependencies]; 2007.

  56. Ministry of Health. Practice guidelines for opioid substitution treatment in New Zealand: 2008. Wellington: Ministry of Health; 2008.

    Google Scholar 

  57. Havemann-Reinecke U, Küfner H, Schneider U, Günthner A, Schalast N, Vollmer HC. AWMF-Leitlinien: Postakutbehandlung bei Störungen durch Opioide [AWMF guidelines for post-acute treatment of opioid use disorders]. Sucht. 2004;50(4):226–57.

    Article  Google Scholar 

  58. Leavitt S, Shinderman M, Maxwell S, Eap CB, Paris P. When, “enough” is not enough: new perspectives on optimal methadone maintenance dose. Mt Sinai J Med. 2000;67(5&6):404–11.

    CAS  PubMed  Google Scholar 

  59. Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano LB, Dougherty RH, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv. 2014;65(2):146–57. doi:10.1176/appi.ps.201300235.

    Article  PubMed  Google Scholar 

  60. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence 2009. Cochrane Database Syst Rev. 2009;3:CD002209. doi:10.1002/14651858.CD002209.pub2.

    PubMed  Google Scholar 

  61. Markham JK, Emmerson JL, Owen NV. Teratogenicity studies of methadone HCl in rats and rabbits. Nature. 1971;233(5318):342–3.

    Article  CAS  PubMed  Google Scholar 

  62. Gerber W, Schramm L. Comparative teratogenicity of morphine, heroin, and methadone in the hamster. Pharmacologist. 1969;11:248.

    Google Scholar 

  63. Jurand A. Teratogenic activity of methadone hydrochloride in mouse and chick embryos. J Embryol Exp Morphol. 1973;30(2):449–58.

    CAS  PubMed  Google Scholar 

  64. Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol. 2011;204(4):314 e1–11. doi:10.1016/j.ajog.2010.12.039.

    Article  PubMed  CAS  Google Scholar 

  65. Mactier H, Shipton D, Dryden C, Tappin DM. Reduced fetal growth in methadone-maintained pregnancies is not fully explained by smoking or socio-economic deprivation. Addiction. 2014;109(3):482–8. doi:10.1111/add.12400.

    Article  PubMed  Google Scholar 

  66. Navaneethakrishnan R, Tutty S, Sinha C, Lindow SW. The effect of maternal methadone use on the fetal heart pattern: a computerised CTG analysis. Br J Obstet Gynaecol. 2006;113(8):948–50. doi:10.1111/j.1471-0528.2006.01020.x.

    Article  CAS  Google Scholar 

  67. Jansson LM, Dipietro J, Elko A. Fetal response to maternal methadone administration. Am J Obstet Gynecol. 2005;193(3 Pt 1):611–7. doi:10.1016/j.ajog.2005.02.075.

    Article  CAS  PubMed  Google Scholar 

  68. Parikh R, Hussain T, Holder G, Bhoyar A, Ewer AK. Maternal methadone therapy increases QTc interval in newborn infants. Arch Dis Child Fetal Neonatal Ed. 2011;96(2):F141–3. doi:10.1136/adc.2009.181701.

    Article  CAS  PubMed  Google Scholar 

  69. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy: effects and management. Obstet Gynecol Clin N Am. 1998;25(1):139–51.

    Article  CAS  Google Scholar 

  70. Cleary BJ, Donnelly J, Strawbridge J, Gallagher PJ, Fahey T, Clarke M, et al. Methadone dose and neonatal abstinence syndrome—systematic review and meta-analysis. Addiction. 2010;105(12):2071–84. doi:10.1111/j.1360-0443.2010.03120.x.

    Article  PubMed  Google Scholar 

  71. Cleary BJ, Eogan M, O’Connell MP, Fahey T, Gallagher PJ, Clarke T, et al. Methadone and perinatal outcomes: a prospective cohort study. Addiction. 2012;107(8):1482–92. doi:10.1111/j.1360-0443.2012.03844.x.

    Article  PubMed  Google Scholar 

  72. Cleary BJ, Reynolds K, Eogan M, O’Connell MP, Fahey T, Gallagher PJ, et al. Methadone dosing and prescribed medication use in a prospective cohort of opioid-dependent pregnant women. Addiction. 2013;108(4):762–70. doi:10.1111/add.12078.

    Article  PubMed  Google Scholar 

  73. Pizarro D, Habli M, Grier M, Bombrys A, Sibai B, Livingston J. Higher maternal doses of methadone does not increase neonatal abstinence syndrome. J Subst Abuse Treat. 2011;40(3):295–8. doi:10.1016/j.jsat.2010.11.007.

    Article  PubMed  Google Scholar 

  74. Jones HE, Jansson LM, O’Grady KE, Kaltenbach K. The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicol Teratol. 2013;39:110–5. doi:10.1016/j.ntt.2013.05.003.

    Article  CAS  PubMed  Google Scholar 

  75. Hulse GK, Milne E, English DR, Holman CDJ. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction. 1997;92(11):1571–9. doi:10.1111/j.1360-0443.1997.tb02877.x.

    Article  CAS  PubMed  Google Scholar 

  76. Kandall SR, Albin S, Lowinson J, Berle B, Eidelman AI, Gartner LM. Differential effects of maternal heroin and methadone use on birthweight. Pediatrics. 1976;58(5):681–5.

    CAS  PubMed  Google Scholar 

  77. Jones HE, Haug N, Silverman K, Stitzer M, Svikis D. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug Alcohol Depend. 2001;61(3):297–306. doi:10.1016/S0376-8716(00)00152-6.

    Article  CAS  PubMed  Google Scholar 

  78. Svikis DS, Lee JH, Haug NA, Stitzer ML. Attendance incentives for outpatient treatment: effects in methadone- and nonmethadone-maintained pregnant drug dependent women. Drug Alcohol Depend. 1997;48(1):33–41.

    Article  CAS  PubMed  Google Scholar 

  79. Connaughton JF, Reeser D, Schut J, Finnegan LP. Perinatal addiction: outcome and management. Am J Obstet Gynecol. 1977;129(6):679–86.

    Article  CAS  PubMed  Google Scholar 

  80. Burns L, Mattick RP, Lim K, Wallace C. Methadone in pregnancy: treatment retention and neonatal outcomes. Addiction. 2007;102(2):264–70.

    Article  PubMed  Google Scholar 

  81. Provincial Council for Maternal and Child Health. Neonatal abstinence syndrome (NAS) clinical practice guidelines 2012. http://www.pqcnc.org/documents/nas/nasresources/NASGuidelines.pdf. Accessed Jul 31 2015.

  82. Stanhope TJ, Gill LA, Rose C. Chronic opioid use during pregnancy: maternal and fetal implications. Clin Perinatol. 2013;40(3):337–50. doi:10.1016/j.clp.2013.05.015.

    Article  PubMed  Google Scholar 

  83. Srivastava A, Kahan M. Methadone induction doses: are our current practices safe? J Addict Dis. 2006;25(3):5–13. doi:10.1300/J069v25n03_02.

    Article  PubMed  Google Scholar 

  84. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev. 2003;3:CD002208. doi:10.1002/14651858.CD002208.

    PubMed  Google Scholar 

  85. Shiu JR, Ensom MHH. Dosing and monitoring of methadone in pregnancy: literature review. Can J Hosp Pharm. 2012;65(5):380–6.

    PubMed  PubMed Central  Google Scholar 

  86. Farid WO, Dunlop SA, Tait RJ, Hulse GK. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol. 2008;6(2):125–50. doi:10.2174/157015908784533842.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009.

    Google Scholar 

  88. Jansson LM, Dipietro JA, Velez M, Elko A, Knauer H, Kivlighan KT. Maternal methadone dosing schedule and fetal neurobehaviour. J Matern Fetal Neonatal Med. 2009;22(1):29–35. doi:10.1080/14767050802452291.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Wittmann B, Segal S. A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation. In J Addict. 1991;26:213–8.

    CAS  Google Scholar 

  90. Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs (Treatment Improvement Protocol Series 43) [report no. (SMA) 12-4214]. Rockville: US Department of Health and Human Services; 2005.

  91. Albright B, de la Torre L, Skipper B, Price S, Abbott P, Rayburn W. Changes in methadone maintenance therapy during and after pregnancy. J Subst Abuse Treat. 2011;41(4):347–53. doi:10.1016/j.jsat.2011.05.002.

    Article  PubMed  Google Scholar 

  92. Pace CA, Kaminetzky LB, Winter M, Cheng DM, Saia K, Samet JH, et al. Postpartum changes in methadone maintenance dose. J Subst Abuse Treat. 2014;47(3):229–32. doi:10.1016/j.jsat.2014.04.004.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend. 2009;104(1–2):73–7. doi:10.1016/j.drugalcdep.2009.03.020.

    Article  CAS  PubMed  Google Scholar 

  94. McNicholas LF, Holbrook AM, O’Grady KE, Jones HE, Coyle MG, Martin PR, et al. Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication. Addiction. 2012;107(Suppl 1):91–7. doi:10.1111/j.1360-0443.2012.04043.x.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Jones HE, Chisolm MS, Jansson LM, Terplan M. Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research. Addiction. 2013;108(2):233–47. doi:10.1111/j.1360-0443.2012.03811.x.

    Article  PubMed  Google Scholar 

  96. Welle-Strand GK, Skurtveit S, Jones HE, Waal H, Bakstad B, Bjarko L, et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a national cohort study of opioid-agonist treatment of pregnant women in Norway from 1996 to 2009. Drug Alcohol Depend. 2013;127(1–3):200–6. doi:10.1016/j.drugalcdep.2012.07.001.

    Article  CAS  PubMed  Google Scholar 

  97. Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction. 2006;101(2):275–81. doi:10.1111/j.1360-0443.2006.01321.x.

    Article  PubMed  Google Scholar 

  98. Lacroix I, Berrebi A, Garipuy D, Schmitt L, Hammou Y, Chaumerliac C, et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol. 2011;67(10):1053–9. doi:10.1007/s00228-011-1049-9.

    Article  CAS  PubMed  Google Scholar 

  99. Salisbury AL, Coyle MG, O’Grady KE, Heil SH, Martin PR, Stine SM, et al. Fetal assessment before and after dosing with buprenorphine or methadone. Addiction. 2012;107(Suppl 1):36–44. doi:10.1111/j.1360-0443.2012.04037.x.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Jones HE, O’Grady KE, Johnson RE, Velez M, Jansson LM. Infant neurobehavior following prenatal exposure to methadone or buprenorphine: results from the neonatal intensive care unit network neurobehavioral scale. Subst Use Misuse. 2010;45(13):2244–57. doi:10.3109/10826084.2010.484474.

    Article  PubMed  Google Scholar 

  101. Coyle MG, Salisbury AL, Lester BM, Jones HE, Lin H, Graf-Rohrmeister K, et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction. 2012;107(Suppl 1):63–73. doi:10.1111/j.1360-0443.2012.04040.x.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Meyer MC, Johnston AM, Crocker AM, Heil SH. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. J Addict Med. 2015;9(2):81–6. doi:10.1097/adm.0000000000000092.

    Article  CAS  PubMed  Google Scholar 

  103. Holbrook AM, Baxter JK, Jones HE, Heil SH, Coyle MG, Martin PR, et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction. 2012;107(Suppl 1):83–90. doi:10.1111/j.1360-0443.2012.04042.x.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014;65(2):158–70. doi:10.1176/appi.ps.201300256.

    Article  PubMed  Google Scholar 

  105. Jones HE, Johnson RE, Jasinski DR, O’Grady KE, Chisholm CA, Choo RE, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79(1):1–10. doi:10.1016/j.drugalcdep.2004.11.013.

    Article  CAS  PubMed  Google Scholar 

  106. Soyka M. Buprenorphine use in pregnant opioid users: a critical review. CNS Drugs. 2013;27(8):653–62. doi:10.1007/s40263-013-0072-z.

    Article  CAS  PubMed  Google Scholar 

  107. Nanovskaya T, Deshmukh S, Brooks M, Ahmed MS. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther. 2002;300(1):26–33.

    Article  CAS  PubMed  Google Scholar 

  108. Meyer M, Crocker AM, Heil SH, Johnston AM. Buprenorphine induction during pregnancy: cardiovascular changes in response to opioid withdrawal. Am J Obstet Gynecol. 2014;204(Suppl 1):S344.

    Article  Google Scholar 

  109. Debelak K, Morrone WR, O’Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy—initial patient care and outcome data. Am J Addict. 2013;22(3):252–4. doi:10.1111/j.1521-0391.2012.12005.x.

    Article  PubMed  Google Scholar 

  110. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction (Treatment Improvement Protocol Series 40) [report no. (SMA) 04-3939]. Rockville: US Department of Health and Human Services; 2004.

  111. Tompkins DA, Bigelow GE, Harrison J, Johnson R, Fudala P, Strain E. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 2009;105(1–2):154–9.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Johnston AM, Mandell TW, Meyer M. Treatment of opioid dependence in pregnancy: Vermont guidelines 2010. https://www.med.uvm.edu/VCHIP/downloads/VCHIP_1%20TREATMENT_VT_GUIDELINES.pdf. Accessed on Jul 01 2015.

  113. Agence Française de Sécurité Sanitaire des Produits de Santé. Initiation et suivi du traitement substitutif de la pharmacodépendance majeure aux opiacés par buprénorphine haut dosage. Paris: Agence Française de Sécurité Sanitaire des Produits de Santé; 2011.

  114. O’Connor A, Alto W, Musgrave K, Gibbons D, Llanto L, Holden S, et al. Observational study of buprenorphine treatment of opioid-dependent pregnant women in a family medicine residency: reports on maternal and infant outcomes. J Am Board Fam Med. 2011;24(2):194–201. doi:10.3122/jabfm.2011.02.100155.

    Article  PubMed  Google Scholar 

  115. Jones HE, Dengler E, Garrison A, O’Grady KE, Seashore C, Horton E, et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug Alcohol Depend. 2014;134:414–7. doi:10.1016/j.drugalcdep.2013.11.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. US Food and Drug Administration. Drugs@FDA. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018932s017lbl.pdf. Accessed Jul 30 2015.

  117. Hulse GK, O’Neill G, Pereira C, Brewer C. Obstetric and neonatal outcomes associated with maternal naltrexone exposure. Aust N Z J Obstet Gynaecol. 2001;41(4):424–8.

    Article  CAS  PubMed  Google Scholar 

  118. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011;4:CD001333. doi:10.1002/14651858.CD001333.pub4.

    PubMed  Google Scholar 

  119. Hulse G, O’Neil G. Using naltrexone implants in the management of the pregnant heroin user. Aust N Z J Obstet Gynaecol. 2002;42(5):569–73.

    Article  CAS  PubMed  Google Scholar 

  120. Hulse GK, O’Neil G, Arnold-Reed DE. Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user. Int J Gynaecol Obstet. 2004;85(2):170–1. doi:10.1016/j.ijgo.2003.10.001.

    Article  CAS  PubMed  Google Scholar 

  121. Waal H. Is sustained release natrexone an option for heroin-dependent pregnant women? Addiction. 2013;108(2):252–3. doi:10.1111/j.1360-0443.2012.03940.x.

    Article  PubMed  Google Scholar 

  122. Soyka M, Kranzler HR, van den Brink W, Krystal J, Moller HJ, Kasper S, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: opioid dependence. World J Biol Psychiatry. 2011;12(3):160–87. doi:10.3109/15622975.2011.561872.

    Article  PubMed  Google Scholar 

  123. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD. Opioid detoxification in pregnancy. Obstet Gynecol. 1998;92(5):854–8.

    Article  CAS  PubMed  Google Scholar 

  124. Luty J, Nikolaou V, Bearn J. Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat. 2003;24:363–7.

    Article  PubMed  Google Scholar 

  125. Stewart RD, Nelson DB, Adhikari EH, McIntire DD, Roberts SW, Dashe JS, et al. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol. 2013;209(3):267 e1–5. doi:10.1016/j.ajog.2013.05.026.

    Article  PubMed  Google Scholar 

  126. Wong S, Ordean A, Kahan M. Society of Obstetricians and Gynecologists of Canada. SOGC clinical practice guidelines: substance use in pregnancy. Int J Gynaecol Obstet. 2011;114(2):190–202.

    Article  PubMed  Google Scholar 

  127. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006;144(2):127–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Meyer M, Paranya G. Keefer Norris A, Howard D. Intrapartum and postpartum analgesia for women maintained on buprenorphine during pregnancy. Eur J Pain. 2010;14(9):939–43. doi:10.1016/j.ejpain.2010.03.002.

    Article  CAS  PubMed  Google Scholar 

  129. Meyer M, Wagner K, Benvenuto A, Plante D, Howard D. Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy. Obstet Gynecol. 2007;110(2 Pt 1):261–6. doi:10.1097/01.AOG.0000275288.47258.e0.

    Article  CAS  PubMed  Google Scholar 

  130. Hoflich AS, Langer M, Jagsch R, Bawert A, Winklbaur B, Fischer G, et al. Peripartum pain management in opioid dependent women. Eur J Pain. 2012;16(4):574–84. doi:10.1016/j.ejpain.2011.08.008.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Jones HE, O’Grady K, Dahne J, Johnson R, Lemoine L, Milio L, et al. Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy. Am J Drug Alcohol Abuse. 2009;35(3):151–6. doi:10.1080/00952990902825413.

    Article  PubMed  PubMed Central  Google Scholar 

  132. Eyler EC. Chronic and acute pain and pain management for patients in methadone maintenance treatment. Am J Addict. 2013;22(1):75–83. doi:10.1111/j.1521-0391.2013.00308.x.

    Article  PubMed  Google Scholar 

  133. Creekmore F, Lugo R, Weiland K. Postoperative opiate analgesia requirements of smokers and nonsmokers. Ann Pharmacother. 2004;38(6):949–53.

    Article  PubMed  Google Scholar 

  134. Mannelli P, Peindl K, Masand PS, Patkar AA. Long-acting injectable naltrexone for the treatment of alcohol dependence. Expert Rev Neurother. 2007;7(10):1265–77. doi:10.1586/14737175.7.10.1265.

    Article  CAS  PubMed  Google Scholar 

  135. Reece-Stremtan S, Marinelli K. Academy of Breastfeeding Medicine. ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. Breastfeed Med. 2015;10(3):135–41.

    Article  PubMed  Google Scholar 

  136. Begg EJ, Malpas TJ, Hackett LP, Ilett KF. Distribution of R- and S-methadone into human milk during multiple, medium to high oral dosing. Br J Clin Pharmacol. 2001;52(6):681–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Jansson LM, Choo R, Velez ML, Harrow C, Schroeder JR, Shakleya DM, et al. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics. 2008;121(1):106–14. doi:10.1542/peds.2007-1182.

    Article  PubMed  Google Scholar 

  138. Ilett KF, Hackett LP, Gower S, Doherty DA, Hamilton D, Bartu AE. Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment. Breastfeed Med. 2012;7:269–74. doi:10.1089/bfm.2011.0096.

    Article  PubMed  Google Scholar 

  139. Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics. 2006;117(6):e1163–9. doi:10.1542/peds.2005-1561.

    Article  PubMed  Google Scholar 

  140. O’Connor AB, Collett A, Alto WA, O’Brien LM. Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy. J Midwifery Womens Health. 2013;58(4):383–8. doi:10.1111/jmwh.12009.

    Article  PubMed  Google Scholar 

  141. Jansson LM, Velez M, Harrow C. Methadone maintenance and lactation: a review of the literature and current management guidelines. J Hum Lact. 2004;20(1):62–71. doi:10.1177/0890334403261027.

    Article  PubMed  Google Scholar 

  142. Hayes MJ, Brown MS. Epidemic of prescription opiate abuse and neonatal abstinence. JAMA. 2012;307(18):1974–5. doi:10.1001/jama.2012.4526.

    Article  CAS  PubMed  Google Scholar 

  143. Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012;107:5–27. doi:10.1111/j.1360-0443.2012.04035.x.

    Article  PubMed  PubMed Central  Google Scholar 

  144. Jones HE, Fischer G, Heil SH, Kaltenbach K, Martin PR, Coyle MG, et al. Maternal Opioid Treatment: human Experimental Research (MOTHER)—approach, issues and lessons learned. Addiction. 2012;107:28–35. doi:10.1111/j.1360-0443.2012.04036.x.

    Article  PubMed  PubMed Central  Google Scholar 

  145. Newman RG, de Rothschild BE, Gevertz SG. Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy. J Addict Dis. 2011;30(4):318–22. doi:10.1080/10550887.2011.609806.

    Article  PubMed  Google Scholar 

  146. Winhusen T, Wilder C, Wexelblatt SL, Theobald J, Hall ES, Lewis D, et al. Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome. Contemp Clin Trials. 2014;39(1):158–65. doi:10.1016/j.cct.2014.08.009.

    Article  PubMed  Google Scholar 

  147. Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79–87. doi:10.1111/add.12333.

    Article  PubMed  PubMed Central  Google Scholar 

  148. Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat. 2010;39(4):340–52. doi:10.1016/j.jsat.2010.07.009.

    Article  PubMed  Google Scholar 

  149. Gryczynski J, Mitchell SG, Jaffe JH, Kelly SM, Myers CP, O’Grady KE, et al. Retention in methadone and buprenorphine treatment among African Americans. J Subst Abuse Treat. 2013;45(3):287–92. doi:10.1016/j.jsat.2013.02.008.

    Article  PubMed  PubMed Central  Google Scholar 

  150. Holbrook AM, Jones HE, Heil SH, Martin PR, Stine SM, Fischer G, et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug Alcohol Depend. 2013;132(1–2):329–34. doi:10.1016/j.drugalcdep.2013.02.031.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Kakko J, Gronbladh L, Svanborg KD, von Wachenfeldt J, Ruck C, Rawlings B, et al. A stepped-care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry. 2007;164(5):797–803. doi:10.1176/appi.ajp.164.5.797.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Addiction Sciences Division, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, 3131 Harvey Avenue, Cincinnati, OH, 45229, USA

    Christine M. Wilder & Theresa Winhusen

  2. Department of Veterans Affairs Medical Center, 3200 Vine Street, Cincinnati, OH, 45220, USA

    Christine M. Wilder

Authors
  1. Christine M. Wilder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Theresa Winhusen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christine M. Wilder.

Ethics declarations

Conflicts of interest

Neither Christine Wilder nor Theresa Winhusen has any conflicts of interest to report.

Funding

No funding was received for this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wilder, C.M., Winhusen, T. Pharmacological Management of Opioid Use Disorder in Pregnant Women. CNS Drugs 29, 625–636 (2015). https://doi.org/10.1007/s40263-015-0273-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-015-0273-8

Keywords

Search

Navigation